Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial.
Fish oil has been used effectively in the treatment of cardiovascular disease via triglyceride reduction and inflammation modulation. This study aimed to assess the effects of fish oil on patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia. Eighty participants with...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4520650?pdf=render |
| _version_ | 1811343678713626624 |
|---|---|
| author | Yu Qin Yong Zhou Shi-Hui Chen Xiao-Lan Zhao Li Ran Xiang-Long Zeng Ying Wu Jun-Li Chen Chao Kang Fu-Rong Shu Qian-Yong Zhang Man-Tian Mi |
| author_facet | Yu Qin Yong Zhou Shi-Hui Chen Xiao-Lan Zhao Li Ran Xiang-Long Zeng Ying Wu Jun-Li Chen Chao Kang Fu-Rong Shu Qian-Yong Zhang Man-Tian Mi |
| author_sort | Yu Qin |
| collection | DOAJ |
| description | Fish oil has been used effectively in the treatment of cardiovascular disease via triglyceride reduction and inflammation modulation. This study aimed to assess the effects of fish oil on patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia. Eighty participants with NAFLD associated with hyperlipidemia were randomly assigned to consume fish oil (n=40, 4 g/d) or corn oil capsules (n=40, 4 g/d) for 3 months in a double-blind, randomized clinical trial. Blood levels of lipids, glucose and insulin, liver enzymes, kidney parameters and cytokines at baseline and the end of the study were measured. Seventy people finished the trial. Plasma concentrations of eicosapentaenoic acid and docosahexaenoic acid significantly increased in the fish oil group after intervention. After adjustment for age, gender and BMI, fish oil significantly decreased fasting serum concentrations of total cholesterol, triglyceride, apolipoprotein B and glucose (by (mean±SD) 0.49±0.43 mmol/L, 0.58±0.89 mmol/L, 0.28±0.33 g/L and 0.76±0.56 mmol/L, respectively, P<0.05), as well as alanine aminotransferase and γ-glutamyl transpeptidase levels (by (median (interquartile)) 9.0(0.5, 21.5) and 7.0(2.2, 20.0) IU/L, respectively, P<0.05), significantly increased serum adiponectin levels (by 1.29±0.62 μg/mL, P<0.001), and reduced serum levels of tumor necrosis factor α, leukotrienes B4, fibroblast growth factor 21 (FGF21), cytokeratin 18 fragment M30 and prostaglandin E2 (by 1.70±1.18 pg/mL, 0.59±0.28 ng/mL, 121±31 pg/mL, 83±60 IU/L and 10.9±2.3 pg/mL, respectively, P<0.001). Corn oil had no effect except for increasing serum creatinine concentrations by 7.7±8.9 μmol/L (P=0.008). The effects of fish oil on lipids, glucose and γ-glutamyl transpeptidase were positively correlated with the reductions of serum FGF21 and prostaglandin E2 concentrations after adjustment for age, gender and BMI (r = 0.275 to 0.360 and 0.261 to 0.375, respectively, P<0.05). In conclusion, our findings suggest that fish oil can benefit metabolic abnormalities associated with NAFLD treatment.ChiCTR-TRC-12002380. |
| first_indexed | 2024-04-13T19:33:06Z |
| format | Article |
| id | doaj.art-25d73c4eb7064d8cb1be891e47ef1b27 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T19:33:06Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-25d73c4eb7064d8cb1be891e47ef1b272022-12-22T02:33:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013349610.1371/journal.pone.0133496Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial.Yu QinYong ZhouShi-Hui ChenXiao-Lan ZhaoLi RanXiang-Long ZengYing WuJun-Li ChenChao KangFu-Rong ShuQian-Yong ZhangMan-Tian MiFish oil has been used effectively in the treatment of cardiovascular disease via triglyceride reduction and inflammation modulation. This study aimed to assess the effects of fish oil on patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia. Eighty participants with NAFLD associated with hyperlipidemia were randomly assigned to consume fish oil (n=40, 4 g/d) or corn oil capsules (n=40, 4 g/d) for 3 months in a double-blind, randomized clinical trial. Blood levels of lipids, glucose and insulin, liver enzymes, kidney parameters and cytokines at baseline and the end of the study were measured. Seventy people finished the trial. Plasma concentrations of eicosapentaenoic acid and docosahexaenoic acid significantly increased in the fish oil group after intervention. After adjustment for age, gender and BMI, fish oil significantly decreased fasting serum concentrations of total cholesterol, triglyceride, apolipoprotein B and glucose (by (mean±SD) 0.49±0.43 mmol/L, 0.58±0.89 mmol/L, 0.28±0.33 g/L and 0.76±0.56 mmol/L, respectively, P<0.05), as well as alanine aminotransferase and γ-glutamyl transpeptidase levels (by (median (interquartile)) 9.0(0.5, 21.5) and 7.0(2.2, 20.0) IU/L, respectively, P<0.05), significantly increased serum adiponectin levels (by 1.29±0.62 μg/mL, P<0.001), and reduced serum levels of tumor necrosis factor α, leukotrienes B4, fibroblast growth factor 21 (FGF21), cytokeratin 18 fragment M30 and prostaglandin E2 (by 1.70±1.18 pg/mL, 0.59±0.28 ng/mL, 121±31 pg/mL, 83±60 IU/L and 10.9±2.3 pg/mL, respectively, P<0.001). Corn oil had no effect except for increasing serum creatinine concentrations by 7.7±8.9 μmol/L (P=0.008). The effects of fish oil on lipids, glucose and γ-glutamyl transpeptidase were positively correlated with the reductions of serum FGF21 and prostaglandin E2 concentrations after adjustment for age, gender and BMI (r = 0.275 to 0.360 and 0.261 to 0.375, respectively, P<0.05). In conclusion, our findings suggest that fish oil can benefit metabolic abnormalities associated with NAFLD treatment.ChiCTR-TRC-12002380.http://europepmc.org/articles/PMC4520650?pdf=render |
| spellingShingle | Yu Qin Yong Zhou Shi-Hui Chen Xiao-Lan Zhao Li Ran Xiang-Long Zeng Ying Wu Jun-Li Chen Chao Kang Fu-Rong Shu Qian-Yong Zhang Man-Tian Mi Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. PLoS ONE |
| title | Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. |
| title_full | Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. |
| title_fullStr | Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. |
| title_full_unstemmed | Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. |
| title_short | Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. |
| title_sort | fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin e2 in nonalcoholic fatty liver disease associated with hyperlipidemia a randomized clinical trial |
| url | http://europepmc.org/articles/PMC4520650?pdf=render |
| work_keys_str_mv | AT yuqin fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT yongzhou fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT shihuichen fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT xiaolanzhao fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT liran fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT xianglongzeng fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT yingwu fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT junlichen fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT chaokang fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT furongshu fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT qianyongzhang fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial AT mantianmi fishoilsupplementslowerserumlipidsandglucoseincorrelationwithareductioninplasmafibroblastgrowthfactor21andprostaglandine2innonalcoholicfattyliverdiseaseassociatedwithhyperlipidemiaarandomizedclinicaltrial |